An Update On Medicaid Reimbursement By State In 2003

Brianne Porter, PharmD, MS, explores how pharmacists can deliver care to a population of women experiencing life-altering symptoms of urinary incontinence.

AJ Barbarito, Esq, explains how ERISA and Medicare Part D preemption limit state PBM laws and why a private right of action may be the most effective path forward.

Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.

With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.

Investigators link oversight with eroding trust in health authorities and call on future pandemic inquiries to weigh trade-offs.

Lara Zakaria, PharmD, MS, CNS, FMCP, illustrates the breadth of health technology going in and out of community pharmacy practice.

Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.

Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.